Edition:
United Kingdom

Sumitomo Dainippon Pharma Co Ltd (4506.T)

4506.T on Tokyo Stock Exchange

1,600JPY
22 Jan 2018
Change (% chg)

¥16 (+1.01%)
Prev Close
¥1,584
Open
¥1,585
Day's High
¥1,600
Day's Low
¥1,583
Volume
771,000
Avg. Vol
1,361,113
52-wk High
¥2,069
52-wk Low
¥1,397

Chart for

About

Sumitomo Dainippon Pharma Co., Ltd., is a pharmaceutical company. The Japan segment manufactures and sells ethical and general use drugs. The North America segment manufactures, develops, purchases and sells ethical drugs. The China segment manufactures and sells ethical drugs through its consolidated subsidiary. The Other... (more)

Overall

Beta: 0.76
Market Cap(Mil.): ¥604,410.31
Shares Outstanding(Mil.): 397.90
Dividend: 11.00
Yield (%): 1.18

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

BRIEF-Poxel And Sumitomo Dainippon Pharma Announce Initiation Of Phase 3 Program For Imeglimin In Japan

* POXEL AND SUMITOMO DAINIPPON PHARMA ANNOUNCE INITIATION OF PHASE 3 PROGRAM FOR IMEGLIMIN, AN INVESTIGATIONAL THERAPEUTIC AGENT FOR TYPE 2 DIABETES, IN JAPAN

27 Dec 2017

BRIEF-Sumitomo Dainippon Pharma says result of early-retirement program

* Says 86 employees took up the offer of the early-retirement program announced on Sept. 27

25 Dec 2017

BRIEF-Sunovion Receives FDA Approval for Lonhala Magnair Inhalation Solution to Treat COPD

* SUNOVION RECEIVES FDA APPROVAL FOR LONHALA MAGNAIR INHALATION SOLUTION TO TREAT COPD

06 Dec 2017

BRIEF-Sumitomo Dainippon Pharma and Angelini Announce Partnership for Commercialization of Latuda (Lurasidone Hydrochloride) in Europe

* Says it and Angelini S.p.A announced today that the companies have formed a partnership with the goal to expand availability in Europe of Latuda®, an atypical antipsychotic which was created by the co

21 Nov 2017

BRIEF-Sumitomo Dainippon Pharma and Poxel announce strategic partnership for development and commercialization of Imeglimin

* Says it signed an agreement with Poxel SA on Oct. 30, for the development and commercialization of Imeglimin, an investigational therapeutic agent for type 2 diabetes, in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries

30 Oct 2017

BRIEF-Poxel and Sumitomo Dainippon Pharma in partnership to develop and sell Imeglimin in Asia

* SUMITOMO DAINIPPON PHARMA AND POXEL ANNOUNCE STRATEGIC PARTNERSHIP FOR DEVELOPMENT AND COMMERCIALIZATION OF IMEGLIMIN, AN INVESTIGATIONAL THERAPEUTIC AGENT FOR TYPE 2 DIABETES, IN JAPAN, CHINA AND ELEVEN OTHER ASIAN COUNTRIES

30 Oct 2017

BRIEF-Kitasato Institute and Sumitomo Dainippon Pharma signs joint drug discovery research agreement

* Says it and the Kitasato Institute have signed a joint drug discovery research agreement for infections caused by bacteria with antimicrobial resistance (AMR)

24 Oct 2017

BRIEF-R&I affirms Sumitomo Dainippon Pharma's rating at "A" and announces stable outlook -R&I

* Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A" -R&I

03 Oct 2017

BRIEF-Sumitomo Dainippon Pharma to offer early-retirement program

* Says it will offer an early-retirement program to employees, who are above 45 years old and continuous service of above 5 years as of March 31, 2018, and employees is members of manufacturing division as of Sept. 1, 2016

27 Sep 2017

Earnings vs. Estimates